SMART Medical Systems Ltd., a developer and manufacturer of innovative endoscopy products, today reported positive data from a multicenter clinical study (NCT 04708951) comparing the adenoma detection rate (ADR) of its FDA-cleared G-EYE® balloon technology against ENDOCUFF VISION® (ECV) technology in patients undergoing screening or surveillance colonoscopy. Results from this randomized trial, the first head-to-head comparison of these two colonoscopy mechanical enhancement devices, showed that the ADR, particularly for advanced and large adenomas, was higher for the G-EYE® balloon than for the ECV attachment. Seth Gross, MD, Professor, Department of Medicine at NYU Grossman School of Medicine, Clinical Chief, Division of Gastroenterology and Hepatology at NYU Langone Health, and co-author on the abstract, presented the data in an oral session at ACG 2021, which is taking place October 22-27 in Las Vegas (ACG 2021, Presidential Plenary Session 1, Abstract #S233).
Trending
- 43% Lower Mortality Seen in Colorectal Screening Participants (HCP Live)
- BioNTech halts mRNA colorectal cancer vaccine trial after safety review (Reuters)
- Microdroplets may reduce colorectal tumor growth at potentially lower cost (Medical Xpress)
- What it takes to build a gut-health service line (GI & Hepatology News)
- Weight Down, Steps Down: The GLP-1 Catch (Medscape)
- Pediatric Gastroenterology Faces AI Reality Check (Medscape)
- Ayble Health Joins Amazon’s Health Benefits Connector to expand Virtual GI Care Access to Millions of Americans (PR Newswire)
- Guardant Health’s Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening (Guardant Health)
